CN101518646B - Lipase-containing composition - Google Patents
Lipase-containing composition Download PDFInfo
- Publication number
- CN101518646B CN101518646B CN200910106279A CN200910106279A CN101518646B CN 101518646 B CN101518646 B CN 101518646B CN 200910106279 A CN200910106279 A CN 200910106279A CN 200910106279 A CN200910106279 A CN 200910106279A CN 101518646 B CN101518646 B CN 101518646B
- Authority
- CN
- China
- Prior art keywords
- lipase
- liver
- compositions
- fat
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention relates to a lipase-containing composition which belongs to lipase. The lipase-containing composition comprises the components with the parts by weight: 5-9 of lipases, 1-2 of hawkthorn extractives and 1-2 of medlar extractives. The lipase-containing composition can be used for curing or preventing fatty liver diseases or hyperlipoidemia diseases, in particular nonalcoholic fatty liver diseases.
Description
Technical field
The present invention relates to lipase, relate in particular to a kind of compositions that contains lipase.
Background technology
Fatty liver is meant the pathological changes of fatty overheap in the hepatocyte that causes owing to a variety of causes.The positive serious threat human beings'health of fatty liver disease becomes the second largest hepatopathy that is only second to viral hepatitis, has been acknowledged as the common cause of disguised liver cirrhosis.Fatty liver is a kind of common clinical picture, but not a kind of independently disease.The lighter is asymptomatic in its clinical manifestation, and weight person's state of an illness is violent.Generally speaking, fatty liver belongs to the reversibility disease, and early diagnosis and treatment in time often can recover normal.Total fat amount in normal person's the liver, account for liver heavy 5%, include phospholipid, triglyceride, fat acid, cholesterol and cholesterol ester.And the person of suffering from fatty liver, total fat amount can reach 40%-50%, mainly is triglyceride and fat acid, increases and phospholipid, cholesterol and cholesterol ester are only a small amount of.Fatty liver generally is divided into two big types, and one type is alcoholic fatty liver, has only a minority blood fat possibly occur among this type patient and increases.Another kind of is non-alcoholic fatty liver disease, and its reason more complicated comprises obesity, diabetes, hyperlipidemia, medicine and inherited genetic factors etc., also has the agnogenic fatty liver in 40% left and right sides.
The NAFLD drug treatment mainly contains at present: 1) degrease Drug therapy, like lipanthyl, Essentiale N/Essentiale Forte N, simvastatin, lovastatin, pravastatin, fluvastatin, mannose ester, Folium Ginkgo, zhibituo, JIANGZHILING etc.; Lipid lowerers causes ALT to increase easily.2) hepatic treatment, hepatic is of a great variety, mainly contains to promote liver cell regeneration, assist the hepatocyte detoxifcation, dispel and cross fattiness in the liver and improve effect such as hepatic tissue metabolism.Most medicines lack strict double-blind trial, are difficult to assess its definite curative effect; And these medicines have increased the weight of liver function injury through liver metabolism.3) traditional Chinese medical herbal treatment fatty liver generally carries out determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs according to main symptom, with mitigation symptoms.Therapeutic effect is uneven, is difficult to assessment.
Summary of the invention
The object of the present invention is to provide a kind of compositions that contains lipase, it can be used for treatment/prevention fatty liver or hyperlipidemia.
A kind of compositions that contains lipase, said composition comprises the component of following weight portion: lipase 5-9 part, Fructus Crataegi extract 1-2 part, Fructus Lycii extract 1-2 part.
Said compositions also comprises the component of following weight portion: Radix Polygoni Multiflori Preparata extract 1-2 part, Semen Cassiae extract 1-2 part, Radix Et Rhizoma Rhei extract 1-2 part.
Said compositions also comprises the component of following weight portion: inositol 0.1-0.3 part.
Said lipase derives from microorganism.
Said lipase derives from Aspergillus niger, rhizopus, sickle mycete, geotrichum sp, candidiasis, penicillium expansum or penicillium cyclopium.
The enzyme work of said lipase is: 2000-4000u/g.
The enzyme work of said lipase is: 3100u/g.
Fructus Crataegi: its slightly warm in nature sour in the mouth is sweet.Li Shizhen (1518-1593 A.D.) is said in Compendium of Material Medica: " the dissipating fluid-retention food, the meat that disappears is long-pending ... the blood distending pain that stagnates disappears." modern pharmacological research proves that Fructus Crataegi can strengthen myocardial contraction, increases cardiac output, decreased heart rate, the expansion coronary vasodilator has effects such as blood pressure lowering, blood fat reducing.And the property of medicine is gentle, and polyphagia with emaciation has no side effect for a long time.
Fructus Lycii: sweet in the mouth, property is flat.Have protect the liver, liver protection effect.Chinese medicine think can tonifying liver the moon, nourishing the liver blood, replenishing vital essence to improve eyesight.Modern pharmacological research proves: Fructus Lycii ability blood sugar lowering, and suppress fat and in hepatocyte, deposits, promote hepatocyte newborn, and the blood pressure lowering effect is arranged.
Radix Polygoni Multiflori Preparata: Radix Polygoni Multiflori is through the ripe Radix Polygoni Multiflori Preparata that is called of processing system.Radix Polygoni Multiflori Preparata is warm in nature, sweet-bitter flavor." Kaibao Bencao " said: " Radix Polygoni Multiflori replenishing QI and blood, black moustache are liked, improving healthy complexion, obey strengthening bone and muscle, beneficial marrow for a long time, and it is not old to prolong life." successive dynasties traditional Chinese medical science scholar thinks that Radix Polygoni Multiflori Preparata is that tonification is simply kept fit, the good medicine of life lengthening.Modern pharmacology experiment confirm, the Radix Polygoni Multiflori have the effect of blood fat reducing, blood sugar lowering, vessel softening and blood pressure lowering.
Semen Cassiae: have another name called Semen Cassiae, because of it has the merit that makes eye bright, so the laudatory title of " Herba Senecionis Scandentis " and " going back gb 1 " is arranged again.Its cold nature, sweet-bitter flavor.Fry usefulness.Effect with liver heat removing and eyesight improving, replenishing YIN and removing heat, loosening bowel to relieve constipation.Modern study proves that Semen Cassiae water logging agent and ethanol preserved material have the effect of blood pressure lowering, blood fat reducing and relieving constipation.
Radix Et Rhizoma Rhei: be the good medicine that rushes down Bian relieving constipation, heat-clearing and toxic substances removing simply, generally all be used for acute heat diseased wood constipation knot.Modern pharmacological research finds that it also has blood pressure lowering, cholesterol reducing effect except that the relieving constipation by purgation effect is arranged.Low dose then has digestion promoting function.Informal dress to obesity, hypertension, coronary heart disease, hyperlipemic patients, all has good effect in a small amount.
A kind of compositions that contains lipase according to the invention, its oral or non-oral administration all is safe.Be used for when oral, can be made into conventional solid preparation such as tablet, powder, granule, capsule, pill, drop pill, buccal tablets etc., process liquid preparation such as water or oil-suspending agent or other liquid preparations such as syrup, elixir etc.; When being used for parenteral, can be made into solution, water or oiliness suspending agent etc. that intravenous injection or intramuscular injection are used.
A kind of compositions that contains lipase according to the invention; Be configured for treating/preventing the medicine of fatty liver with its pharmaceutically acceptable carrier; This carrier can be the conventional pharmaceutical carrier of pharmaceutical field, for example: diluent, excipient such as water etc., filler such as starch, sucrose etc.; Adhesive such as cellulose derivative, alginate, gelatin and polyvinylpyrrolidone; Wetting agent such as glycerol; Disintegrating agent such as agar, calcium carbonate and calcium bicarbonate; Absorption enhancer such as quaternary ammonium compound; Surfactant such as hexadecanol; Absorb carrier such as Kaolin and soap clay; Lubricant such as Pulvis Talci, sodium stearate and magnesium, Polyethylene Glycol etc.Can also in compositions, add other adjuvant such as flavouring agent, sweeting agent etc. in addition.
Fatty liver or hyperlipidemia, especially non-alcoholic fatty liver disease can effectively be treated/prevented to the compositions that contains lipase according to the invention.
The specific embodiment
Embodiment 1
A kind of compositions that contains lipase comprises the component of following weight portion: 6 parts of lipases, 1.5 parts of Fructus Crataegi extracts, 1.5 parts of Fructus Lycii extracts.
Embodiment 2
A kind of compositions that contains lipase comprises the component of following weight portion: 9 parts of lipases, 2 parts of Fructus Crataegi extracts, 1 part of Fructus Lycii extract, 1 part of Radix Polygoni Multiflori Preparata extract, 1 part of Semen Cassiae extract, 1 part of Radix Et Rhizoma Rhei extract.
Embodiment 3
A kind of compositions that contains lipase comprises the component of following weight portion: 5 parts of lipases, 1 part of Fructus Crataegi extract, 1 part of Fructus Lycii extract, 1 part of Radix Polygoni Multiflori Preparata extract, 1 part of Semen Cassiae extract, 1 part of Radix Et Rhizoma Rhei extract.
Embodiment 4
A kind of compositions that contains lipase comprises the component of following weight portion: 7 parts of lipases, 1.5 parts of Fructus Crataegi extracts, 1.5 parts of Fructus Lycii extracts, 0.15 part of inositol.
Test Example
Embodiment 1 said a kind of preventive and therapeutic effect that contains the compositions of lipase to non-alcoholic fatty liver disease.
One, experiment material
1.1 high lipid food: self-control, prescription is 2% cholesterol, 10% Adeps Sus domestica, 0.2% sodium cholate, 5% yolk powder, 82.8% normal feedstuff.
Cholesterol: the Qidong, Hunan produces lot number: 071226 with the biochemical factory of letter
Adeps Sus domestica: commercially available leaf fat boils.
Yolk powder: commercially available egg self-control.
Sodium cholate: the Qidong, Hunan produces lot number 071109 with the biochemical factory of letter.
Normal feedstuff: Nanfang Hospital's Experimental Animal Center provides.
1.2 mensuration reagent
TC measures test kit: Zhongsheng Beikong Biological Science & Technology Co., Ltd. produces.Lot number 080171.
TG measures test kit: Zhongsheng Beikong Biological Science & Technology Co., Ltd. produces, lot number 080201.
HDL-C measures test kit: east, Zhejiang bowl biological engineering company limited is produced lot number 08060579.
1.3 ether: Tianjin Milky Way chemical reagent factory produces, lot number 20070812.
1.4 laboratory animal
Wistar rat (SPF level), male, body weight 160-180 (g).Nanfang Medical Univ's Experimental Animal Center provides, the animal quality certification: 2006A052.
1.5 experimental apparatus
The full-automatic biochemical analyzer: Olympus AV-640 type, Japan produces.
Microtome: LEICARM2245.
Two, laboratory animal
55 of Wistar rats, male, body weight 160-180g, the SPF level is provided the quality certification: 2006A052 by Nanfang Medical Univ's Experimental Animal Center.Raising in observation ward's (checking and affirm word 2007C083 number in Guangdong, meets the barrier grade standard) of central air-conditioning, 24.0 ± 1.0 ℃ of temperature, lighting hours 12 hours.
Three, receive the reagent thing
The embodiment 1 said compositions that contains lipase, wherein lipase enzyme 3100u/g alive.
The medicine preparation: electronic balance takes by weighing an amount of compositions, is diluted to 0.52g/ml, 0.26g/ml, 0.13g/ml with 1%CMC-Na.
Administration volume: 1ml/100g body weight.
Four, method
1, test method
Get 70 of Wistar male rats, etherization, the eye socket venous plexus is got blood, and centrifugalize serum is measured TC, TG content with Olympus AV-640 type full automatic biochemical apparatus, rejects the rat of numerical exception.Choose 55 of qualified rats, press TC, TG contents level, be divided into 5 groups at random, 11 every group, i.e. (1) normal control group; (2) model control group is irritated stomach and is given 0.5%CMC-Na; (3)-(5) administration group, lipase dosage are respectively 8060u/kg (be equivalent to the people and intend 2 times of clinical equivalent consumptions), 4030u/kg (be equivalent to the people and intend clinical equivalent dosage), 2015u/kg (be equivalent to the people and intend 0.5 times of clinical equivalent dosage).Receive reagent to grind, be made into desired concn with 0.5%CMC-Na respectively with preceding, the administration volume is the 1ml/100g body weight.Administration same day, except that normal control group feed normal diet, other each group changes high lipid food into.Observe the animal state at duration of test, write down body weight weekly 1 time, and after the modeling administration 12 weeks; The animal fasting can't help water after 16 hours, use etherization, the eye socket venous plexus is got the about 2ml of blood; Centrifugal 10 minutes of 3000r; Get serum, on automatic clinical chemistry analyzer, measure TG, TC, HDL-C content in the serum, and calculate TC/HDL-C ratio.Put to death all animals, win liver and weigh.After observing cardinal principle liver outward appearance, with 10% formaldehyde fixed hepatic tissue, carry out pathological examination, the result sees table 1-3.
2, observation index and evaluation criteria
Automatic clinical chemistry analyzer detects serum TG, TC, HDL-C content.
Hepatopathy inspection of science: after hepatic tissue carries out FFPE, section, conventional H E dyeing; Fat histopathology diagnosis is carried out classification [2] according to lobules of liver fat cell hypertrophy number to the fatty liver degree simultaneously with reference to hepatology branch of Chinese Medical Association fatty liver non-alcoholic hepatopathy group " non-alcoholic fatty liver disease diagnostic criteria " [1]: in the hepatocyte no fat drip be deposited as in 0 minute, lobules of liver＜hepatocyte that hepatocyte that 30% hepatocyte has fat to become 30%-50% in 1 minute, lobules of liver has fat to become 50%-75% in 2 minutes, lobules of liver has that fat becomes 3 fens, the interior hepatocyte more than 75% of lobules of liver has fat to become 4 fens.
3, statistical method
Adopt the SPSS14.0 software kit to analyze, all results all computer directly export.Measurement data relatively adopts one factor analysis of variance LSD method with (mean ± standard deviation) expression between each group.All statistical test all adopt two-sided test, and the P value is less than or equal to 0.05 difference that is considered to checked has statistical significance.
Five, result of the test
1, overview:
Normal group and the increase of model group rat body weight are bigger, but the apparent in view reduction of high, the middle dose groups weight ratio of lipase model group (p＜0.05)
2, lipase is to disorders of lipid metabolism rat body weight and the heavy exponential influence of liver
Table 1. lipase is to disorders of lipid metabolism rat body weight and the heavy exponential influence of liver
Liver index=liver weight/body weight (%)
Model group and matched group be △ △ p＜0.01 relatively;
Administration group and model group are relatively
*P＜0.05
*P＜0.01
3, contain of the influence of the compositions of lipase to rat disorders of lipid metabolism TG content, TC content, HDL-C content, TC/HDL-C ratio
Table 2. contains the influence of the compositions of lipase to rat disorders of lipid metabolism TG content, TC content, HDL-C content, TC/HDL-C ratio
Model group and normal control group be △ p＜0.05 relatively; △ △ p＜0.01
Administration group and model group are relatively
*P＜0.05;
*P＜0.01
4, hepatopathy is of science changes
4.1 12 weekends of gross examination of skeletal muscle, normal control rat liver color is scarlet, clear-cut margin, and matter is soft, smooth surface.The model group rat liver increases, yellow skin, and the edge rust, matter is crisp, and tangent plane has greasy feeling.Administration group rat liver volume obviously increases than normal group, but reduces than model group is obvious, yellow skin, and the edge rust, matter is crisp, and tangent plane has greasy feeling.
4.2 om observation normal control liver tissues of rats section HE dyeing shows that hepatic tissue does not have obvious lipidosis.Model group liver tissues of rats section HE dyeing shows that most of liver tissues of rats 50-75% cell is obvious steatosis.Administration group liver tissues of rats section HE dyeing shows that hepatic tissue cell is the degree and the apparent in view minimizing of model group of obvious steatosis.Table 3. is seen in the score of steatosis degree
Table 3 contains the influence of the compositions of lipase to liver tissues of rats HE dyeing hepatic cell fattydegeneration
Model group and normal control group be △ △ p＜0.01 relatively
Administration group and model group are relatively
*P＜0.05;
*P＜0.01
Six, conclusion (of pressure testing)
The above results shows that modeling group Wistar rat body weight gain after modeling is slow, and appetite reduces, and the animal state is obviously not good, becomes thin, the hair pine, and weight loss is obvious.Administration treated animal state is better than model group, and each dose groups can obviously reduce the heavy index (seeing table 1) of liver.
Modeling is during 12 weeks; Model group animal serum TC, TG content and TC/LDL-CH ratio are all apparently higher than normal control group (p＜0.05 or p＜0.01); And pathologic finding shows that model group animal liver tissue steatosis is set up, and shows that blood fat disorder type fatty liver model forms.Each dose groups of administration group has obvious inhibitory action (seeing table 2) to TG, TC, but TC/LDL-CH is not had influence.Lipase to liver tissues of rats HE dyeing hepatic cell fattydegeneration degree score see table 3, show that the compositions that contains lipase can obviously improve the steatosis of the animal livers that is caused by high lipid food.
In sum, under this experimental condition, tried the compositions that article contain lipase and can obviously be reduced the heavy index of liver,, can be suppressed animal serum TC, TG content, can also significantly be improved the liver fat deposition though TC/LDL-CH ratio is not had influence.Explain that said composition not only has clear improvement to metabolism disorder of blood lipid, also have the effect that the lipidosis that makes liver obviously reduces, reduces the liver fat degeneration.
Obtain and Test Example 1 analog result with embodiment 2, the 3 or 4 said compositionss that the contain lipase rat of feeding; The compositions that contains lipase can obviously reduce the heavy index of liver; Though TC/LDL-CH ratio is not had influence; But can suppress animal serum TC, TG content, can also significantly improve the liver fat deposition.Explain that said composition not only has clear improvement to metabolism disorder of blood lipid, also have the effect that the lipidosis that makes liver obviously reduces, reduces the liver fat degeneration.
Claims (1)
1. compositions that contains lipase; Its effective ingredient is made up of the component of following weight portion: 6 parts of lipases, 1.5 parts of Fructus Crataegi extracts, 1.5 parts of Fructus Lycii extracts, and said lipase derives from Aspergillus niger, rhizopus, sickle mycete, geotrichum sp, candidiasis, penicillium expansum or penicillium cyclopium; The enzyme work of said lipase is: 3100u/g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910106279A CN101518646B (en) | 2009-04-02 | 2009-04-02 | Lipase-containing composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910106279A CN101518646B (en) | 2009-04-02 | 2009-04-02 | Lipase-containing composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101518646A CN101518646A (en) | 2009-09-02 |
| CN101518646B true CN101518646B (en) | 2012-10-03 |
Family
ID=41079576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910106279A Active CN101518646B (en) | 2009-04-02 | 2009-04-02 | Lipase-containing composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101518646B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102225120A (en) * | 2011-06-16 | 2011-10-26 | 安徽安科生物工程（集团）股份有限公司 | Medicine for treating fatty liver and preparation method thereof |
| CN104055926A (en) * | 2013-03-22 | 2014-09-24 | 储绍清 | Dietotherapy composition capable of controlling fatty liver |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1105557A (en) * | 1994-10-11 | 1995-07-26 | 吴宏伟 | Method for preparation of weight-loosing medicine and its products |
| CN1535717A (en) * | 2003-04-11 | 2004-10-13 | 成都地奥制药集团有限公司 | Chinese medicine clove and application of its extract in preparation of medicine for reducing weight |
| CN100368519C (en) * | 2005-06-02 | 2008-02-13 | 深圳市绿微康生物工程有限公司 | Aspergillus niger lipase and its preparation method |
-
2009
- 2009-04-02 CN CN200910106279A patent/CN101518646B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1105557A (en) * | 1994-10-11 | 1995-07-26 | 吴宏伟 | Method for preparation of weight-loosing medicine and its products |
| CN1535717A (en) * | 2003-04-11 | 2004-10-13 | 成都地奥制药集团有限公司 | Chinese medicine clove and application of its extract in preparation of medicine for reducing weight |
| CN100368519C (en) * | 2005-06-02 | 2008-02-13 | 深圳市绿微康生物工程有限公司 | Aspergillus niger lipase and its preparation method |
Non-Patent Citations (4)
| Title |
|---|
| 孙欣峰等.降脂中药的研究现状及展望.《中国中医药信息杂志》.2001,第8卷(第1期),25-27. * |
| 孙灵霞等.肌醇生产、应用研究及前景展望.《粮食与油脂》.2004,(第11期),6-8. * |
| 王海燕等.脂肪酶的研究进展及其在饲料中的应用.《饲料工业》.2007,第28卷(第6期),14-17. * |
| 程京艳等.药食同源——枸杞子与山楂.《首都医药》.2006,第13卷(第2期),41-43. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101518646A (en) | 2009-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101011561B (en) | Modern traditional Chinese medicine oral preparation huanglianwendan decoction and production method thereof | |
| CN101836725B (en) | Application of red rice residue product in preparing health-care food for lowering blood fat | |
| CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
| CN102895320A (en) | Medicinal food formula and medicinal edible preparation for preventing and treating hyperuricemia and gout | |
| CN101518646B (en) | Lipase-containing composition | |
| CN109528904A (en) | A kind of kidney-tonifying health-care, boosting qi and nourishing yin, pharmaceutical composition of high-content ginsenoside and preparation method thereof | |
| CN103816278B (en) | Composition for reducing blood sugar and application thereof | |
| CN113134057A (en) | Compound traditional Chinese medicine preparation for treating hyperlipemia and preparation method thereof | |
| CN1325089C (en) | Chinese patent medicine on health food composition and its use | |
| CN106579392A (en) | Composition for alleviating delayed onset muscle soreness | |
| CN105685994A (en) | Healthcare food capable of assisting in blood lipid reduction and preparation method and application of healthcare food capable of assisting in blood lipid reduction | |
| KR20100133079A (en) | Herbal extracts composition for the prevention of alcoholic fatty liver, hyperlipidemia and hangover | |
| CN102266428B (en) | Anti-ageing Chinese medicinal composition and preparation method and application thereof | |
| CN105125635A (en) | Traditional Chinese medicine composition capable of boosting immunity and application thereof | |
| CN108926595A (en) | A kind of health care product with protection liver and hypolipemic function | |
| CN109010579A (en) | A kind of antioxidant and anti-aging Chinese traditional compound medicine and preparation method thereof | |
| CN107898920A (en) | A kind of mouth containing product and preparation method for diabetes | |
| CN113599447A (en) | Traditional Chinese medicine composition for improving phlegm-dampness constitution and preparation method and application thereof | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| CN111480846A (en) | Health-care product for assisting in reducing blood fat and improving immunity | |
| CN101642528B (en) | Production process of compound soft ginsengs | |
| CN111494445A (en) | Health-care composition with functions of enhancing immunity and relieving fatigue and preparation method thereof | |
| CN104257960A (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease and applications of composition | |
| CN109731089A (en) | A kind of composition and its preparation method and application adjusting liver-stomach disharmony | |
| CN104940387B (en) | A kind of Chinese medicine composition for treating NASH and its preparation and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Lipase-containing composition Effective date of registration: 20150826 Granted publication date: 20121003 Pledgee: Bank of Jiangsu Limited by Share Ltd Shenzhen branch Pledgor: Shenzhen leveking Biology Engineering Co. Ltd.|Wuhan University Registration number: 2015990000723 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20161117 Granted publication date: 20121003 Pledgee: Bank of Jiangsu Limited by Share Ltd Shenzhen branch Pledgor: Shenzhen leveking Biology Engineering Co. Ltd.|Wuhan University Registration number: 2015990000723 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170615 Address after: 247100 Shuanglong Road 1, Chizhou economic and Technological Development Zone, Anhui, China Patentee after: Anhui Lvweikang Biological Technology Co. Ltd. Address before: 518057 a biological incubator building, 2-112, 113, high tech Zone, Nanshan District hi tech Zone, Guangdong, Shenzhen Patentee before: Luweikang Bio-Engineering Co., Ltd., Shenzhen City |